2. Signaling Pathways
  3. Cytoskeleton
  4. Myosin

Myosin

Myosin

Related Products

PDF 0.33 MB

Myosins are mechanoenzymes that interact with actin filaments and hydrolyse ATP to generate movement and force. This enables myosins to propel the sliding of actin filaments, to produce tension on actin filaments and to walk along these filaments. As a result, myosins can regulate the structure and dynamics of the actin cytoskeleton and affect the localization and transport of cellular components. The different myosins are grouped into classes on the basis of their motor domains. There are 35 known classes of myosin, and humans have 40 myosin genes that fall into 13 classes (I, II, III, V, VI, VII, IX, X, XV, XVI, XVIII, XIX and XXXV).

Myosins are actin-dependent motors that participate in a diverse range of crucial activities, including muscle contraction, intracellular trafficking, cell division, motility, actin cytoskeletal organisation and cell signaling. Myosin malfunction has been implicated in a variety of disorders including deafness, hypertrophic cardiomyopathy, Usher syndrome, Griscelli syndrome and cancer.

Myosin light chain kinase (MLCK) is an enzyme that activates the myosin light chain to exert its function related to cytoskeleton contraction and tight junction regulation. In most cells, MLCK is a transducer for signalling MLC phosphorylation in response to Ca2+ binding to MLCK-associated calmodulin. MLCK-mediated MLC phosphorylation and actomyosin contractility is important in muscle contraction, cell migration, and endo/exocytic processes, and is recognized for its central role in signalling endothelial cell-cell adhesion and barrier function.

Myosin Isoform Specific Products:

Myosin Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13441
    (-)-Blebbistatin
    		Inhibitor 98.68%
    (-)-Blebbistatin is a selective inhibitor of the ATPase activity of non-muscle myosin II.
    (-)-Blebbistatin
  • HY-13813
    Blebbistatin
    		Inhibitor 99.64%
    Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function. Blebbistatin blocks cell migration.
    Blebbistatin
  • HY-109037
    Mavacamten
    		Modulator 99.94%
    Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
    Mavacamten
  • HY-15417
    ML-7 hydrochloride
    		Inhibitor 99.88%
    ML-7 hydrochloride is a naphthalene sulphonamide derivative, potently inhibits MLCK (IC50=300 nM). ML-7 hydrochloride also inhibits YAP/TAZ.
    ML-7 hydrochloride
  • HY-100912
    W-7 hydrochloride
    		Inhibitor 99.96%
    W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias.
    W-7 hydrochloride
  • HY-17681
    Myosin-IN-5
    		Inhibitor
    Myosin-IN-5 (example 3) is a selective cardiac myosin inhibitor with an IC50 of 1.5 μM. Myosin-IN-5 shows much less effective in inhibiting skeletal myofibril activity (IC50 of 43.4 μM). Myosin-IN-5 can be used for the study of hypertrophic cardiomyopathy (HCM) and cardiac diseases.
    Myosin-IN-5
  • HY-P11373
    α-Myosin (614-643)
    α-Myosin (614-643) is a segment of polypeptide of the heavy chain of cardiac α-myosin. α-Myosin has a strong ability to induce autoimmune myocarditis.
    α-Myosin (614-643)
  • HY-180792
    CK-571
    		Inhibitor
    CK-571 is a potent and selective inhibitor of smooth muscle myosin-2 (SMM), with an IC50 value of 86 nM. CK-571 exhibits IC50 values for cardiac muscle myosin (CMM), skeletal muscle myosin (SKM), and non-muscle myosin-2A (NMM-2A) of 2.3, 42, and 0.58 μM, respectively. CK-571 can be used for research on asthma, chronic obstructive pulmonary disease, and other smooth muscle-related diseases.
    CK-571
  • HY-14233
    Omecamtiv mecarbil
    		Activator 99.83%
    Omecamtiv mecarbil (CK-1827452) is a selective cardiac myosin activator.
    Omecamtiv mecarbil
  • HY-139465
    Aficamten
    		Inhibitor 99.86%
    Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM).
    Aficamten
  • HY-109128
    Danicamtiv
    		Activator 99.59%
    Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency.
    Danicamtiv
  • HY-120870
    para-Nitroblebbistatin
    		Inhibitor 99.0%
    para-Nitroblebbistatin is a derivative of Blebbistatin (HY-13813) and an inhibitor of myosin II. para-Nitroblebbistatin is photostable, non-cytotoxic, and non-phototoxic. para-Nitroblebbistatin can serve as an ideal substitute for Blebbistatin (HY-13813) to study the role of myosin II in physiology, development, and cell biology.
    para-Nitroblebbistatin
  • HY-Y0413
    Biacetyl monoxime
    		Inhibitor 98.0%
    Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiac muscle contraction inhibitor. Biacetyl monoxime is also a well-characterized non-competitive inhibitor of chemical and motile activity of skeletal muscle myosin-II. Biacetyl monoxime induces sarcoplasmic reticulum Ca2+ release.
    Biacetyl monoxime
  • HY-149662
    TMDJ-035
    		99.92%
    TMDJ-035 is a high-affinity, selective RyR2 inhibitor with an EC50 of 0.0130 μM. TMDJ-035 reduces RyR2 protein expression without affecting action potential-induced Ca2+ transients. TMDJ-035 decreases ATP content and intracellular Ca2+ levels. TMDJ-035 inhibits arrhythmias in a CPVT mouse model carrying mutant RyR2s. TMDJ-035 has no effect on electrocardiogram parameters or cardiac systolic function. TMDJ-035 exacerbates heart failure in mouse myocardial infarction models and hypoxic cardiomyocytes by altering cardiac function, causing tissue damage, promoting inflammatory infiltration, collagen deposition, and changes in Myosin heavy chain/actin expression. TMDJ-035 can be used in studies related to heart failure, catecholaminergic polymorphic ventricular tachycardia, and arrhythmias.
    TMDJ-035
  • HY-148799
    Sevasemten
    		Inhibitor 99.32%
    Sevasemten is an orally active, selective allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten decreases muscle damage biomarkers and fibrosis while increasing muscle strength and activity in in Duchenne muscular dystrophy disease models.
    Sevasemten
  • HY-100932
    ML-9
    		Inhibitor 99.86%
    ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation.
    ML-9
  • HY-16690
    BTS
    		Inhibitor 99.79%
    BTS (N-Benzyl-p-toluenesulfonamide) is a potent and selective inhibitor of skeletal muscle myosin II subfragment 1 (S1) ATPase activity, with an IC50s of ~5 µM for actin- and Ca2+-stimulated myosin S1 ATPase. BTS specifically inhibits the contraction of fast skeletal muscle fibers.
    BTS
  • HY-111474
    Para-aminoblebbistatin
    		Inhibitor 99.90%
    Para-aminoblebbistatin is the inhibitor for myosin II. Para-aminoblebbistatin inhibits the ATPase activity of myosin II, thereby blocking the formation and contraction of the actin-myosin network. Para-aminoblebbistatin is a non-fluorescent and photostable Blebbistatin (HY-13813) derivative.
    Para-aminoblebbistatin
  • HY-Y0073
    4-Hydroxyacetophenone
    		Activator 99.98%
    4-Hydroxyacetophenone (P-hydroxyacetophenone) is a major hepatoprotective and choleretic compound found in Artemisia and Illicium plants, exhibiting antiviral and anti-inflammatory effects against hepatitis B virus. Additionally, 4-Hydroxyacetophenone inhibits cancer cell adhesion, invasion, and migration by remodeling actin. 4-Hydroxyacetophenone holds promise for research in the fields of inflammatory diseases and cancer.
    4-Hydroxyacetophenone
  • HY-P1029
    MLCK inhibitor peptide 18
    		Inhibitor 98.04%
    MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.
    MLCK inhibitor peptide 18
Cat. No. Product Name / Synonyms Application Reactivity
Myosin Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.